Visual Hallucinations Associated with High Posaconazole Concentrations in Serum.
作者信息
Parkes Leighanne O, Cheng Matthew P, Sheppard Donald C
机构信息
Division of Infectious Diseases and Department of Medical Microbiology, McGill University Health Centre, Montreal, Canada
Division of Infectious Diseases and Department of Medical Microbiology, McGill University Health Centre, Montreal, Canada.
出版信息
Antimicrob Agents Chemother. 2015 Dec 7;60(2):1170-1. doi: 10.1128/AAC.02739-15. Print 2016 Feb.
Abstract
摘要
相似文献
1
Visual Hallucinations Associated with High Posaconazole Concentrations in Serum.
Antimicrob Agents Chemother. 2015 Dec 7;60(2):1170-1. doi: 10.1128/AAC.02739-15. Print 2016 Feb.
2
Efficacy and safety of posaconazole for chronic pulmonary aspergillosis.
Clin Infect Dis. 2010 Dec 15;51(12):1383-91. doi: 10.1086/657306. Epub 2010 Nov 5.
3
Long-term treatment of refractory invasive fungal infection with posaconazole: additive value of therapeutic drug monitoring.
Acta Clin Belg. 2011 May-Jun;66(3):231-2. doi: 10.2143/ACB.66.3.2062555.
4
[Usefulness of monitoring plasma voriconazole concentration in patients with chronic necrotizing pulmonary aspergillosis].
Nihon Kokyuki Gakkai Zasshi. 2009 Feb;47(2):93-7.
5
Adverse reactions to voriconazole.
Clin Infect Dis. 2004 Oct 15;39(8):1241-4. doi: 10.1086/424662. Epub 2004 Sep 23.
6
Recurrence of chronic pulmonary aspergillosis after discontinuation of maintenance treatment by antifungal triazoles.
J Infect Chemother. 2014 Jun;20(6):375-9. doi: 10.1016/j.jiac.2014.02.003. Epub 2014 Mar 26.
7
What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice?
Antimicrob Agents Chemother. 2009 Aug;53(8):3608-9; author reply 609-10. doi: 10.1128/AAC.00256-09.
8
[Complex visual hallucinations induced by voriconazole].
Med Clin (Barc). 2009 Jun 27;133(4):156-7. doi: 10.1016/j.medcli.2008.09.022.
9
Use of posaconazole delayed-release tablets for treatment of invasive aspergillosis.
Mycoses. 2015 May;58(5):313-4. doi: 10.1111/myc.12309. Epub 2015 Feb 27.
10
Voriconazole-micafungin combination therapy for acute lymphoblastic leukemia.
Pediatr Int. 2010 Feb;52(1):137-41. doi: 10.1111/j.1442-200X.2009.02947.x.
引用本文的文献
1
Supratherapeutic Posaconazole Concentration in a Pediatric Transplant Patient With Confirmed Infection.
J Pediatr Pharmacol Ther. 2021;26(7):753-757. doi: 10.5863/1551-6776-26.7.753. Epub 2021 Sep 24.
2
Current and promising pharmacotherapeutic options for candidiasis.
Expert Opin Pharmacother. 2021 May;22(7):867-887. doi: 10.1080/14656566.2021.1873951. Epub 2021 Feb 4.
3
Pharmacokinetics and Pharmacodynamics of Posaconazole.
Drugs. 2020 May;80(7):671-695. doi: 10.1007/s40265-020-01306-y.
4
The Pharmacology of Visual Hallucinations in Synucleinopathies.
Front Pharmacol. 2019 Dec 9;10:1379. doi: 10.3389/fphar.2019.01379. eCollection 2019.
5
Treatment by Posaconazole Tablets, Compared to Posaconazole Suspension, Does Not Reduce Variability of Posaconazole Trough Concentrations.
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.00484-19. Print 2019 Oct.
6
Antifungal Prophylaxis with Posaconazole Delayed-Release Tablet and Oral Suspension in a Real-Life Setting: Plasma Levels, Efficacy, and Tolerability.
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.02655-17. Print 2018 Jun.
7
Posaconazole Plasma Concentrations on Days Three to Five Predict Steady-State Levels.
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5595-9. doi: 10.1128/AAC.00389-16. Print 2016 Sep.
本文引用的文献
1
Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis.
Mycoses. 2015 Jul;58(7):432-6. doi: 10.1111/myc.12339. Epub 2015 Jun 23.
2
Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies.
Antimicrob Agents Chemother. 2015 Aug;59(8):4424-8. doi: 10.1128/AAC.00581-15. Epub 2015 May 18.
3
Voriconazole, an antifungal triazol that causes visual side effects, is an inhibitor of TRPM1 and TRPM3 channels.
Invest Ophthalmol Vis Sci. 2015 Feb 3;56(2):1367-73. doi: 10.1167/iovs.14-15270.
4
Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.
Antimicrob Agents Chemother. 2014 Oct;58(10):5758-65. doi: 10.1128/AAC.03050-14. Epub 2014 Jul 21.
5
Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.
Antimicrob Agents Chemother. 2014 Jul;58(7):3610-7. doi: 10.1128/AAC.02686-13. Epub 2014 Apr 14.
6
Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.
Expert Rev Anti Infect Ther. 2013 Sep;11(9):931-41. doi: 10.1586/14787210.2013.826989.
7
Antifungal Azoles: Structural Insights into Undesired Tight Binding to Cholesterol-Metabolizing CYP46A1.
Mol Pharmacol. 2013 Jul;84(1):86-94. doi: 10.1124/mol.113.085902. Epub 2013 Apr 19.
8
Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brain.
J Biol Chem. 2010 Oct 8;285(41):31783-95. doi: 10.1074/jbc.M110.143313. Epub 2010 Jul 28.
9
Phospholipidosis in neurons caused by posaconazole, without evidence for functional neurologic effects.
Toxicol Pathol. 2009 Dec;37(7):902-10. doi: 10.1177/0192623309348521.
10
Posaconazole concentrations in the central nervous system.
J Antimicrob Chemother. 2008 Dec;62(6):1468-70. doi: 10.1093/jac/dkn409. Epub 2008 Sep 28.
Zotero 插件